B+
Bull case
20%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-05-27 · RankAlpha Sentiment Codex
INDP
Indaptus TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is mostly optionality: if management secures fresh capital on tolerable terms and can point to a credible funded development path for Decoy20, the stock could re-rate sharply from a depressed base.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Balance-sheet and runway risk remain acute: the company reported roughly $1.5 million of cash at March 31, 2026 and expected funding only through Q2 2026 [#10-Q-2026-05-15].
Momentum
88
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.00 · Bull $2.50 · Bear $0.25Analysis 2026-05-27; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-27 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $10.00
Why
Momentum88 · Δ7d -
Value41 · Δ7d -0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Balance-sheet and runway risk remain acute: the company reported roughly $1.5 million of cash at March 31, 2026 and expected funding only through Q2 2026 [#10-Q-2026-05-15].
- • Execution risk is high because any delay in financing, partnership execution, or strategic repositioning could force additional dilution or a more distressed capital raise.
- • The bear case is that cash remains tight, burn continues, and the company needs additional equity or debt before a clear clinical or strategic catalyst emerges, with the program reset limiting near-term upside.
Catalyst clock
2026-05-15
Q1 results showed lower loss but did not solve cash burn
Lead driver: Value · See fundamentals
Momentum
88
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 88.5 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-27. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.00
Analysis reference price unavailable
Analysis 2026-05-27 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.25
Analysis reference price unavailable
Analysis 2026-05-27 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$133.24M
Beta
0.99
Shares Out
113.24M
P/E (TTM) · Derived
-0.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.22
Rev YoY
-
EPS YoY
-99.8%
Gross Margin
-
Op Margin
-
Net Debt
-$8.51M
Current Ratio
19.48
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data